Swedbank AB Decreases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Swedbank AB reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 318,362 shares of the biopharmaceutical company’s stock after selling 14,000 shares during the period. Swedbank AB owned about 0.25% of Halozyme Therapeutics worth $18,223,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Boston Trust Walden Corp purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $23,211,000. Creative Planning increased its holdings in Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 11,249 shares in the last quarter. Boston Partners raised its position in Halozyme Therapeutics by 14.1% during the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after acquiring an additional 77,976 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Finally, Segall Bryant & Hamill LLC grew its position in shares of Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after purchasing an additional 49,856 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 60,000 shares of company stock worth $3,425,000 in the last ninety days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $47.79 on Wednesday. The company has a market cap of $6.08 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.45 and a beta of 1.29. The firm’s 50 day moving average is $54.28 and its two-hundred day moving average is $53.68. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Benchmark reissued a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Finally, JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.